3D Tissue Models

Pharmacology: Merck

Total Score People Score Events Score
17 17 11
Date Event Presentation Speakers
February 24, 2011 Targeting P13K / mTOR Signaling in Cancer Clinical development of MK-2206: A potent oral allosteric AKT inhibitor Li Yan
February 13, 2011 Inositide Signaling in Pharmacology and Disease (X1) PI 3-Kinases (X2) | Using Biomarker Tools to Position PI3K Pathway Inhibitors in Clinical Studies Pearl S. Huang
October 20, 2010 6th Annual Meeting of the Oligonucleotide Therapeutics Society Preclinical Development of RNA Therapeutics Michael Flanagan
microRNA mimics and diagnostics Lee P. Lim
November 2, 2009 Track 4: Fourth Annual GPCR-based drug discovery CGRP Receptor Antagonists for the Acute Treatment of Migraine Donnette Staas
October 13, 2009 Fourth Annual Drug Repositioning Summit Knowledge Management Technologies for Drug Repurposing Natalia Novac
June 9, 2009 Inaugural The Expanding Impact of New Animal Models in Drug Safety Predictive Methodologies in Ophthalmic Pharmaceutical Discovery and Safety Robert L. Peiffer
Closing Panel Discussion: What can we do to Create Better Testing Models so that Toxicity Results in Animals are more Predictive? Robert L. Peiffer
February 23, 2009 Advances and Progress in Drug Design VIII KNOWLEDGE BASED DRUG DESIGN Matthias Frech
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics New(er) Tools for Rapid Metabolite Identification Kevin Bateman
Minimizing Drug Toxicities During Drug Discovery and Development | Altas Ballroom (Town & Country/San Diego) Tom Baillie
Unusual Interspecies Differences in the Metabolism of a Cathepsin K Inhibitor Deborah Nicoll-Griffith
Unusual Interspecies Differences in the Metabolism of a Cathepsin K Inhibitor Deborah Nicoll-Griffith
June 18, 2008 Accelerating Anticancer Agent Development and Validation Workshop Decision-Making in Oncology Drug Development Stephen H Friend
Panel Discussion Stephen H Friend
October 16, 2007 Inaugural HDAC inhibitors: Meeting the Challenges of Chemical Development of HDAC Inhibitors Oct (16 -17) OVERCOMING THE CHALLENGES: ADVANCED HDAC INHIBITORS (08:30-11:10) Thomas A. Miller
OVERCOMING THE CHALLENGES - ADVANCED HDAC INHIBITORS: Histone Deacetylase Inhibitors: Bench to Bedside (08:40-09:10) Thomas A. Miller
Roundtable Discussion Sessions - Topic: HDAC Inhibitors and Drug Selectivity Issues (07:30-08:30) Thomas A. Miller
Keynote Session: Executive Panel: Delivering Drugs for Difficult Targets(08:40-09:40) Lex Van der Ploeg, Shama Kajiji
NEXT GENERATION HDAC INHIBITORS: Structural Biology of Human Histone Deacetylase Enzymes (11:10-11:40) Andrea Carfi
NEXT GENERATION HDAC INHIBITORS (10:35-12:40) Thomas A. Miller, Andrea Carfi
NEXT GENERATION HDAC INHIBITORS: Chairperson’s Remarks (10:35-10:40) Thomas A. Miller
October 11, 2007 Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12) PROFILING TO OPTIMIZE EFFICACY (08:30-14:00) Berta Strulovici
PROFILING TO OPTIMIZE EFFICACY: Panel Discussion - The Value of Doing Systems Biology after HTS (12:15-12:45) Berta Strulovici
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.